J-LEAPS peptide and LEAPS dendritic cell vaccines

Microb Biotechnol. 2012 Mar;5(2):203-13. doi: 10.1111/j.1751-7915.2011.00278.x. Epub 2011 Sep 6.


The J-LEAPS vaccines contain a peptide from β-2-microglobulin covalently attached to disease-related peptides of 8-30 amino acids which contain a T cell epitope. The J-LEAPS vaccines can initiate a protective Th1 immune response or modulate an ongoing Th17 autoimmune response to the peptide. J-LEAPS vaccines activate and direct the nature of the subsequent immune response by promoting the maturation of precursor cells into a unique type of dendritic cell that produces interleukin 12, but not IL-1 or tumour necrosis factor, and presents the antigenic peptide to T cells. Adoptive transfer of JgD-LEAPS dendritic cells, matured with an anti-HSV-1 vaccine, promoted antigen-specific Th1 protection against lethal challenge with the virus. J-LEAPS peptide immunogens and J-LEAPS dendritic cell vaccines have potential applications for antimicrobial prevention and therapy, treatment of autoimmune diseases, and for cancer immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antigens / genetics
  • Antigens / immunology*
  • Autoimmune Diseases / therapy
  • Communicable Disease Control / methods
  • Dendritic Cells / immunology*
  • Humans
  • Immunotherapy / methods*
  • Neoplasms / therapy
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / immunology
  • beta 2-Microglobulin / genetics
  • beta 2-Microglobulin / immunology*


  • Antigens
  • Recombinant Fusion Proteins
  • beta 2-Microglobulin